Back to search
FDAFDA · Food and drugs·Recall number D-0382-2026

Nilotinib Capsules, 200 mg per capsule, packaged in cartons, Rx only, Manufactured for: Cipla USA, Inc., 10 Independence Boulevard, Suite 300, Warren, NJ 07059, Outer carton: 112 capsules (4 individual packs containing 28 capsules each), NDC 69097-032-74; Inner carton: 28 capsules (4 blisters of 7 capsules), NDC 69097-032-56; Foil blister: NDC 69097-032-17

Published March 11, 2026 · Recall initiated: February 18, 2026

Summary

FDA records drug Class III recall D-0382-2026, published March 11, 2026 and initiated February 18, 2026. Recalling firm: Cipla USA, Inc.; Status: Ongoing; Reported quantity: 164 cartons; Lot: Lot #: 5GJ0223, Exp 04/30/2027. Class III means the product is not likely to cause adverse health consequences.

Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Failed Tablet/Capsule Specifications: Observed OOS results at 6-months long-term stability condition for Description test and Appearance by Visual Inspection test.

What to do

Voluntary: Firm initiated · Letter

Get an email if NILOTINIB has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
NILOTINIB
Manufacturer
Cipla USA, Inc.
Distributor
U.S.A. Nationwide
Lot
Lot #: 5GJ0223, Exp 04/30/2027
Risk classification
Class III
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Nilotinib Capsules, 200 mg per capsule, packaged in cartons, Rx only, Manufactured for: Cipla USA, Inc., 10 Independence Boulevard, Suite 300, Warren, NJ 07059, Outer carton: 112 capsules (4 individual packs containing 28 capsules each), NDC 69097-032-74; Inner carton: 28 capsules (4 blisters of 7 capsules), NDC 69097-032-56; Foil blister: NDC 69097-032-17 recalled?

Yes. FDA published recall D-0382-2026 on March 11, 2026. Reported hazard: Failed Tablet/Capsule Specifications: Observed OOS results at 6-months long-term stability condition for Description test and Appearance by Visual Inspection test.

What should I do if I have this product?

Voluntary: Firm initiated · Letter

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: NILOTINIB.